Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Assets Average (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Assets Average for 9 consecutive years, with $277.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average rose 50.09% year-over-year to $277.4 million, compared with a TTM value of $277.4 million through Dec 2025, up 50.09%, and an annual FY2025 reading of $231.4 million, up 32.07% over the prior year.
  • Assets Average was $277.4 million for Q4 2025 at Zevra Therapeutics, up from $263.2 million in the prior quarter.
  • Across five years, Assets Average topped out at $277.4 million in Q4 2025 and bottomed at -$426000.0 in Q3 2022.
  • Average Assets Average over 5 years is $138.8 million, with a median of $136.5 million recorded in 2021.
  • The sharpest move saw Assets Average plummeted 100.31% in 2022, then surged 28797.18% in 2023.
  • Year by year, Assets Average stood at $135.1 million in 2021, then tumbled by 57.46% to $57.5 million in 2022, then skyrocketed by 170.91% to $155.7 million in 2023, then increased by 18.75% to $184.8 million in 2024, then surged by 50.09% to $277.4 million in 2025.
  • Business Quant data shows Assets Average for ZVRA at $277.4 million in Q4 2025, $263.2 million in Q3 2025, and $214.5 million in Q2 2025.